Medindia
Medindia LOGIN REGISTER
Advertisement

For the Treatment of Benign Prostatic Hyperplasia, Competition From Emerging Novel Injectable Agents Will Reduce Botox's Market Share

Tuesday, February 16, 2010 General News
Advertisement
High Cost of Injectable Therapies Will Limit Their Overall Uptake in Benign Prostatic Hyperplasia, According to New Findings from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Gisselle Morales

Christopher Comfort

781-296-2691

781-296-2597

[email protected]

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close